Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13665490 | 0.92 | KDM4E (0.42) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL13654432 | 0.88 | KCNH2 (0.43) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL13654587 | 0.88 | CYP11B2 (0.44) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL13665753 | 0.86 | SLC6A4 (0.40) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL13665767 | 0.86 | MAPT (0.40) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL13666165 | 0.85 | MAT2A (0.37) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL13665759 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL13665755 | 0.84 | USP14 (0.43) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL13654435 | 0.81 | KDM4E (0.37) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL13665495 | 0.80 | NR1I2 (0.36) | KDM4EALDH1A1LMNAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | KDM4E 1637/4885ALDH1A1 1514/4885LMNA 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.